| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d374f418d1f0a3939fe0b5594814aee1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_feeaae83efd7f931710abe68558f2483
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dd94ae6400a7379948eaae2f78f75c1c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_972fba12e555c3904699bc9c9534274c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1931fee6ef1efe4894f9c5f409e56966 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2842
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-709 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6887 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2012-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec404fab8483e216ff4c70f1f15e0310
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08ebecb1e6a230573d916c92750c660d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92130ae4bdb4326cda4ae9fe5e904a8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f07afbb439cabc0b7f5de82a3f489089
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c0a051f8e2e942d8fca27e4997fcf44 |
| publicationDate |
2014-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2014005281-A1 |
| titleOfInvention |
Method of Predicting Increased Risk of Suffering Statin-induced Adverse Drug Reactions |
| abstract |
Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (statins) are prescribed to lower serum cholesterol levels and reduce the risk of CVD. Despite the success of statins, many patients abandon treatment owing to neuromuscular adverse drug reactions (ADRs). Genome-wide association studies have identified the single-nucleotide polymorphism (SNP) rs4149056 in the SLCO1B1 gene as being associated with an increased risk for statin-induced ADRs. n By studying slow-channel syndrome transgenic mouse models, this invention determined that statins trigger ADRs in mice expressing the mutant allele of the rs137852808 SNP in the nicotinic acetylcholine receptor (nAChR) α-subunit gene CHRNA1. Mice expressing this allele show a remarkable contamination of end-plates with caveolin-1 and develop early signs of neuromuscular degeneration upon statin treatment. The invention demonstrates that genes coding for nAChR subunits may contain variants associated with statin-induced ADRs. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200034125-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020060211-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102205831-B1 |
| priorityDate |
2012-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |